A renowned ophthalmologist and vitreoretinal surgeon joins Ainnova's Medical Board.
Ainnova Tech announced Dr. Maziar Lalezary, M.D. as Medical Advisor and member of its Medical Board. He joins to accelerate the development of AI-powered early-detection solutions for retinal imaging.
His clinical expertise helps ensure VisionAI meets the highest standards of accuracy and clinical relevance.
Dr. Maziar Lalezary, M.D., FASRS, is a board-certified ophthalmologist and fellowship-trained vitreoretinal surgeon who completed his residency and retina fellowship at the Vanderbilt Eye Institute. He treats conditions including macular degeneration, diabetic retinopathy and retinal vascular disease.
As Medical Advisor, his expertise helps guide the clinical development of Ainnova's retinal-imaging solutions.
Ainnova Tech is a healthcare technology company focused on revolutionizing early disease detection using artificial intelligence. Its platform, VisionAI, analyzes retinal images to detect early markers of diseases such as diabetic retinopathy — with a growing portfolio spanning cardiovascular, metabolic, liver and kidney risk. Ainnova is dedicated to making healthcare more proactive, accessible and efficient.
Source: Press release on Digital Journal ↗
Contact: Ainnova Tech — info@ainnovatech.com